This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
Title of project or programme
| Title of PI | Basic science and preclinical development of cell transplantation for basal ganglia disorders |
Principal Investigators of project/programme grant
| Title | Forname | Surname | Institution | Country |
| Professor | Stephen | Dunnett | Cardiff University | UK |
Address of institution of lead PI
| Institution | Cardiff University |
| Street Address | Cardiff School of Biosciences, Life Sciences Building, Museum Avenue |
| City | Cardiff |
| Postcode | CF10 3AX |
Country
- United Kingdom
Source of funding information
Medical Research Council
Total sum awarded (Euro)
1300218.87
Start date of award
01-02-2011
Total duration of award in months
36
The project/programme is most relevant to
- Parkinson’s disease
- Huntington’s disease
Keywords
Research abstract in English
The UK is taking an international lead in developing stem cells for cell-based therapy applicable to a broad range of diseases. The purpose of this programme application is to address the translational gap to deliver clinical-grade human neuronal cells from primary, expanded and pluripotent origins for transplantation in clinical trials of human neurodegenerative disease. We complement other stem cell programmes in establishing and maintaining the infrastructure for ethically-sourced, safe, quality-assured processing of cells of clinical grade under regulatory licence, alongside establishing relevant patient cohorts, assessment programmes and clinical trial expertise, without which advances in basic cell biology cannot progress to human use or clinical trial. A major component of this programme is to develop and refine the animal models to evaluate alternative sources of cells with predictive validity of likely functional efficacy in man. Immediate applications are set to commence using primary fetal cells in 2011-2012 in Huntingtons disease and Parkinsons disease, with subsequent applications in stoke, and using expanded fetal progenitors, pending the availability of clinical grade stem cells.
Lay summary
In which category does this research fall?
- Basic research
Basic science and preclinical development of cell transplantation for basal ganglia disorders
Investments > €500k
United Kingdom
Huntington’s disease|Parkinson’s disease & PD-related disorders
2011